Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionnuclear glucocorticoid receptor binding

NRIP1 NCOA6

2.00e-052072GO:0035259
GeneOntologyMolecularFunctionnuclear retinoid X receptor binding

NRIP1 NCOA6

2.66e-052372GO:0046965
GeneOntologyMolecularFunctiontranscription coactivator activity

CITED2 NRIP1 NCOA6

1.16e-0430373GO:0003713
GeneOntologyMolecularFunctionnuclear estrogen receptor binding

NRIP1 NCOA6

1.44e-045372GO:0030331
GeneOntologyMolecularFunctionnuclear retinoic acid receptor binding

NRIP1 NCOA6

1.55e-045572GO:0042974
GeneOntologyMolecularFunctionRNA polymerase II-specific DNA-binding transcription factor binding

CITED2 NRIP1 NCOA6

2.97e-0441773GO:0061629
GeneOntologyMolecularFunctiontranscription coregulator activity

CITED2 NRIP1 NCOA6

7.13e-0456273GO:0003712
GeneOntologyMolecularFunctionDNA-binding transcription factor binding

CITED2 NRIP1 NCOA6

7.90e-0458273GO:0140297
GeneOntologyMolecularFunctiontranscription factor binding

CITED2 NRIP1 NCOA6

1.67e-0375373GO:0008134
GeneOntologyMolecularFunctionnuclear receptor binding

NRIP1 NCOA6

1.78e-0318772GO:0016922
GeneOntologyMolecularFunctionprotein domain specific binding

CITED2 UBR5 NCOA6

2.57e-0387573GO:0019904
GeneOntologyMolecularFunctiontranscription corepressor activity

CITED2 NRIP1

2.65e-0322972GO:0003714
GeneOntologyMolecularFunctionprotein-macromolecule adaptor activity

CITED2 NRIP1 NCOA6

5.74e-03116073GO:0030674
GeneOntologyMolecularFunctionmolecular adaptor activity

CITED2 NRIP1 NCOA6

8.89e-03135673GO:0060090
PathwayREACTOME_HEME_SIGNALING

NRIP1 CHD9 NCOA6

7.84e-074963M41832
PathwayREACTOME_CIRCADIAN_CLOCK

NRIP1 CHD9 NCOA6

2.32e-067063M938
PathwayREACTOME_RORA_ACTIVATES_GENE_EXPRESSION

CHD9 NCOA6

2.30e-051862M26942
PathwayREACTOME_BMAL1_CLOCK_NPAS2_ACTIVATES_CIRCADIAN_GENE_EXPRESSION

CHD9 NCOA6

5.27e-052762M26943
PathwayREACTOME_ACTIVATION_OF_GENE_EXPRESSION_BY_SREBF_SREBP

CHD9 NCOA6

1.29e-044262M27172
PathwayREACTOME_CELLULAR_RESPONSES_TO_STIMULI

CITED2 NRIP1 CHD9 NCOA6

1.61e-0482864M27827
PathwayBIOCARTA_PPARA_PATHWAY

CITED2 NRIP1

1.98e-045262M2404
PathwayREACTOME_TRANSCRIPTIONAL_ACTIVATION_OF_MITOCHONDRIAL_BIOGENESIS

CHD9 NCOA6

2.22e-045562M27145
PathwayREACTOME_REGULATION_OF_CHOLESTEROL_BIOSYNTHESIS_BY_SREBP_SREBF

CHD9 NCOA6

2.22e-045562M27001
PathwayREACTOME_CYTOPROTECTION_BY_HMOX1

CHD9 NCOA6

2.64e-046062M41830
PathwayPID_AR_PATHWAY

NRIP1 NCOA6

2.73e-046162M58
PathwayREACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION

CHD9 NCOA6

5.18e-048462M1008
PathwayREACTOME_MITOCHONDRIAL_BIOGENESIS

CHD9 NCOA6

6.76e-049662M26973
PathwayREACTOME_ADIPOGENESIS

CHD9 NCOA6

8.87e-0411062M48259
PathwayREACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA

CHD9 NCOA6

1.02e-0311862M27316
PathwayREACTOME_METABOLISM_OF_STEROIDS

CHD9 NCOA6

1.73e-0315462M27832
PathwayREACTOME_CELLULAR_RESPONSE_TO_CHEMICAL_STRESS

CHD9 NCOA6

3.18e-0321062M41836
PathwayREACTOME_ORGANELLE_BIOGENESIS_AND_MAINTENANCE

CHD9 NCOA6

6.27e-0329762M27050
PathwayWP_NUCLEAR_RECEPTORS_METAPATHWAY

NRIP1 NCOA6

6.99e-0331462M39428
PathwayREACTOME_DEVELOPMENTAL_BIOLOGY

CLASP2 CHD9 NCOA6

1.65e-02143263M509
PathwayREACTOME_CELLULAR_RESPONSES_TO_STIMULI

CITED2 CHD9

1.75e-0250562MM15548
Pubmed

The Hippocampal Response to Acute Corticosterone Elevation Is Altered in a Mouse Model for Angelman Syndrome.

NRIP1 NCOA6

1.91e-06117236613751
Pubmed

T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities.

NRIP1 NCOA6

6.59e-06207211877444
Pubmed

Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor.

NRIP1 NCOA6

7.28e-06217219596656
Pubmed

Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival.

UBR5 NCOA6

4.23e-05507237974198
Pubmed

FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia.

CLASP2 NRIP1 CHD9

9.73e-054977336774506
Pubmed

Prediction of the coding sequences of mouse homologues of KIAA gene: I. The complete nucleotide sequences of 100 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.

CLASP2 CHD9

1.29e-04877212465718
InteractionPPARA interactions

NRIP1 CHD9 NCOA6

3.18e-069273int:PPARA
InteractionNCOA2 interactions

UBR5 NRIP1 NCOA6

1.15e-0514173int:NCOA2
InteractionNCOA1 interactions

UBR5 NRIP1 NCOA6

1.28e-0514673int:NCOA1
InteractionRXRA interactions

NRIP1 CHD9 NCOA6

1.98e-0516973int:RXRA
InteractionTHRB interactions

NRIP1 CHD9 NCOA6

2.63e-0518673int:THRB
InteractionRXRG interactions

NRIP1 NCOA6

1.11e-044772int:RXRG
InteractionRORB interactions

NRIP1 NCOA6

1.11e-044772int:RORB
InteractionNR1I2 interactions

UBR5 NCOA6

1.16e-044872int:NR1I2
InteractionPPARG interactions

UBR5 NRIP1 NCOA6

1.17e-0430773int:PPARG
InteractionRANGAP1 interactions

CLASP2 UBR5 NCOA6

1.25e-0431473int:RANGAP1
InteractionTULP3 interactions

UBR5 NRIP1 CHD9

1.67e-0434673int:TULP3
InteractionNR1H3 interactions

NRIP1 NCOA6

1.69e-045872int:NR1H3
InteractionSMAD2 interactions

CITED2 UBR5 NCOA6

2.29e-0438573int:SMAD2
InteractionNR1H2 interactions

NRIP1 NCOA6

2.33e-046872int:NR1H2
InteractionCIB1 interactions

UBR5 NRIP1

2.40e-046972int:CIB1
InteractionESRRG interactions

UBR5 NRIP1

2.84e-047572int:ESRRG
InteractionPPARGC1A interactions

NRIP1 NCOA6

3.39e-048272int:PPARGC1A
InteractionFEZ1 interactions

CLASP2 NRIP1

4.08e-049072int:FEZ1
InteractionPRMT2 interactions

UBR5 NCOA6

4.17e-049172int:PRMT2
InteractionGRIP1 interactions

NRIP1 NCOA6

4.64e-049672int:GRIP1
InteractionDAB1 interactions

CLASP2 PCDH18

5.76e-0410772int:DAB1
InteractionTP53BP1 interactions

CLASP2 UBR5 NCOA6

5.95e-0453373int:TP53BP1
InteractionFBXO22 interactions

CLASP2 NRIP1 CHD9

6.18e-0454073int:FBXO22
InteractionTHRA interactions

NRIP1 NCOA6

6.20e-0411172int:THRA
InteractionVDR interactions

NRIP1 NCOA6

8.10e-0412772int:VDR
InteractionCREBBP interactions

CITED2 CLASP2 NCOA6

8.36e-0459973int:CREBBP
InteractionNUP43 interactions

UBR5 CHD9 NCOA6

9.46e-0462573int:NUP43
InteractionTWIST1 interactions

UBR5 CHD9

1.44e-0317072int:TWIST1
InteractionFGF11 interactions

UBR5 CHD9

1.44e-0317072int:FGF11
InteractionWDR48 interactions

CLASP2 UBR5

1.56e-0317772int:WDR48
CoexpressionDACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN

CLASP2 UBR5 NRIP1 CHD9

3.31e-0646674M13522
CoexpressionSCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN

NRIP1 CHD9 PCDH18 NCOA6

3.34e-0646774M1347
CoexpressionSCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN

NRIP1 CHD9 PCDH18 NCOA6

3.85e-0648474MM999
CoexpressionGSE8835_HEALTHY_VS_CLL_CD8_TCELL_UP

CITED2 CHD9 NCOA6

1.50e-0520073M6262
CoexpressionGENTILE_UV_RESPONSE_CLUSTER_D9

CITED2 UBR5

1.98e-052672M13686
CoexpressionSCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX4_DN

NRIP1 CHD9

3.22e-053372M1359
CoexpressionDACOSTA_UV_RESPONSE_VIA_ERCC3_DN

CLASP2 UBR5 NRIP1 CHD9

3.65e-0585674M4500
CoexpressionSCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX4_DN

NRIP1 CHD9

4.05e-053772MM570
CoexpressionDAZARD_RESPONSE_TO_UV_NHEK_DN

UBR5 NRIP1 CHD9

5.02e-0530073M8702
CoexpressionOSMAN_BLADDER_CANCER_UP

CITED2 NRIP1 CHD9

1.20e-0440273M5275
CoexpressionNAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_UP

CITED2 UBR5 CHD9 NCOA6

1.44e-04121574M41122
CoexpressionFLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP

CITED2 CLASP2 NRIP1

3.32e-0456873M4023
CoexpressionIKEDA_MIR30_TARGETS_UP

NRIP1 CHD9

4.02e-0411672M2379
CoexpressionIKEDA_MIR30_TARGETS_UP

NRIP1 CHD9

4.09e-0411772MM931
CoexpressionPECE_MAMMARY_STEM_CELL_DN

UBR5 PCDH18

6.18e-0414472M2535
CoexpressionDAZARD_UV_RESPONSE_CLUSTER_G6

UBR5 CHD9

6.27e-0414572M1810
CoexpressionGSE37534_PIOGLITAZONE_VS_ROSIGLITAZONE_TREATED_CD4_TCELL_PPARG1_FOXP3_TRANSDUCED_DN

UBR5 CHD9

8.10e-0416572M8992
CoexpressionGSE3565_CTRL_VS_LPS_INJECTED_DUSP1_KO_SPLENOCYTES_DN

CLASP2 NRIP1

8.70e-0417172M6321
CoexpressionGSE21033_1H_VS_12H_POLYIC_STIM_DC_UP

NRIP1 NCOA6

9.21e-0417672M7725
CoexpressionGSE17974_0H_VS_6H_IN_VITRO_ACT_CD4_TCELL_UP

CITED2 CHD9

1.08e-0319172M4164
CoexpressionGSE17974_0H_VS_48H_IN_VITRO_ACT_CD4_TCELL_UP

CITED2 CHD9

1.09e-0319272M4174
CoexpressionGSE1112_OT1_CD8AB_VS_HY_CD8AA_THYMOCYTE_RTOC_CULTURE_DN

CLASP2 UBR5

1.13e-0319572M6142
CoexpressionGSE16266_CTRL_VS_LPS_STIM_MEF_UP

NRIP1 CHD9

1.16e-0319872M7219
CoexpressionGSE21360_PRIMARY_VS_QUATERNARY_MEMORY_CD8_TCELL_DN

CITED2 CHD9

1.16e-0319872M7610
CoexpressionGSE13411_NAIVE_VS_SWITCHED_MEMORY_BCELL_DN

CHD9 NCOA6

1.16e-0319872M3242
CoexpressionGSE17721_CTRL_VS_PAM3CSK4_2H_BMDC_UP

CLASP2 NCOA6

1.17e-0319972M3733
CoexpressionGSE19941_IL10_KO_VS_IL10_KO_AND_NFKBP50_KO_LPS_AND_IL10_STIM_MACROPHAGE_UP

CLASP2 UBR5

1.17e-0319972M8115
CoexpressionZHENG_FOXP3_TARGETS_IN_THYMUS_UP

CITED2 CHD9

1.17e-0319972M1746
CoexpressionGAUTAM_EYE_CHOROID_SCLERA_FIBROBLASTS

CHD9 PCDH18

1.17e-0319972M43608
CoexpressionGSE17721_CTRL_VS_POLYIC_0.5H_BMDC_UP

CITED2 NRIP1

1.19e-0320072M3705
CoexpressionGSE27786_BCELL_VS_MONO_MAC_DN

CITED2 PCDH18

1.19e-0320072M4818
CoexpressionGSE14769_UNSTIM_VS_120MIN_LPS_BMDM_DN

CITED2 NRIP1

1.19e-0320072M3504
CoexpressionGSE17721_PAM3CSK4_VS_GADIQUIMOD_8H_BMDC_DN

CLASP2 NCOA6

1.19e-0320072M3973
CoexpressionGSE17721_CTRL_VS_CPG_2H_BMDC_UP

NRIP1 PCDH18

1.19e-0320072M3759
CoexpressionGSE25123_WT_VS_PPARG_KO_MACROPHAGE_ROSIGLITAZONE_STIM_UP

CITED2 NRIP1

1.19e-0320072M7978
CoexpressionGSE12845_IGD_POS_BLOOD_VS_PRE_GC_TONSIL_BCELL_DN

CLASP2 UBR5

1.19e-0320072M3188
CoexpressionGSE27786_ERYTHROBLAST_VS_NEUTROPHIL_DN

UBR5 NCOA6

1.19e-0320072M4876
CoexpressionGSE7460_CTRL_VS_FOXP3_OVEREXPR_TCONV_DN

NRIP1 CHD9

1.19e-0320072M5715
CoexpressionGSE5589_LPS_VS_LPS_AND_IL10_STIM_IL10_KO_MACROPHAGE_45MIN_UP

CITED2 CHD9

1.19e-0320072M6629
CoexpressionGSE28737_FOLLICULAR_VS_MARGINAL_ZONE_BCELL_DN

CITED2 PCDH18

1.19e-0320072M9352
CoexpressionGSE24726_WT_VS_E2_2_KO_PDC_DAY6_POST_DELETION_DN

CITED2 CHD9

1.19e-0320072M8056
CoexpressionZHENG_FOXP3_TARGETS_IN_THYMUS_UP

CITED2 CHD9

1.19e-0320072MM1033
CoexpressionGSE20198_UNTREATED_VS_IL12_IL18_TREATED_ACT_CD4_TCELL_DN

CITED2 UBR5

1.19e-0320072M7373
CoexpressionGSE11961_MARGINAL_ZONE_BCELL_VS_GERMINAL_CENTER_BCELL_DAY40_UP

NRIP1 NCOA6

1.19e-0320072M9317
CoexpressionGSE5542_IFNG_VS_IFNA_AND_IFNG_TREATED_EPITHELIAL_CELLS_24H_UP

CITED2 NCOA6

1.19e-0320072M6535
CoexpressionGSE14769_UNSTIM_VS_60MIN_LPS_BMDM_DN

CITED2 NRIP1

1.19e-0320072M3499
CoexpressionGSE24142_ADULT_VS_FETAL_DN3_THYMOCYTE_UP

UBR5 NRIP1

1.19e-0320072M4584
CoexpressionGSE21670_TGFB_VS_TGFB_AND_IL6_TREATED_STAT3_KO_CD4_TCELL_UP

CITED2 CHD9

1.19e-0320072M7446
CoexpressionGSE5099_UNSTIM_VS_MCSF_TREATED_MONOCYTE_DAY7_UP

CHD9 NCOA6

1.19e-0320072M6584
CoexpressionGSE6674_CPG_VS_PL2_3_STIM_BCELL_DN

UBR5 NCOA6

1.19e-0320072M6938
CoexpressionGSE14350_TREG_VS_TEFF_IN_IL2RB_KO_UP

UBR5 CHD9

1.19e-0320072M3419
CoexpressionGSE7831_UNSTIM_VS_CPG_STIM_PDC_4H_UP

CITED2 NRIP1

1.19e-0320072M6953
CoexpressionGSE27786_LIN_NEG_VS_MONO_MAC_DN

CITED2 NCOA6

1.19e-0320072M4798
CoexpressionGSE20366_TREG_VS_NAIVE_CD4_TCELL_DEC205_CONVERSION_DN

UBR5 NCOA6

1.19e-0320072M4334
CoexpressionMIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN

NRIP1 PCDH18

1.63e-0323572M2256
CoexpressionZHOU_INFLAMMATORY_RESPONSE_FIMA_DN

CITED2 CHD9

2.29e-0327972M250
CoexpressionQI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DY_AT_1DYPOSITIVE

CITED2 NCOA6

2.54e-0329472M40873
CoexpressionAtlasMESO-15 amniotic fluid MSC_vs_MESO-15 blastocyst-Confounder_removed-fold2.0_adjp0.05

CLASP2 UBR5 NRIP1 CHD9 PCDH18

3.04e-05147975PCBC_ratio_MESO-15 amniotic fluid MSC_vs_MESO-15 blastocyst_cfr-2X-p05
ToppCellfacs-Brain_Myeloid-Hippocampus-3m-Myeloid|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CLASP2 NRIP1 CHD9

2.69e-061937306b65110db974f4ef90d3511ff34428976a52c9c
ToppCellfacs-Brain_Myeloid-Hippocampus-3m-Myeloid-microglial_cell|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CLASP2 NRIP1 CHD9

2.69e-06193739c16032bc03df8760ae199e8f19fdafa4c3f1827
ToppCellfacs-Brain_Myeloid-Hippocampus-3m|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CLASP2 NRIP1 CHD9

2.69e-0619373a4f91bca5eaa985982d33a528f7566ffde154d47
ToppCellfacs-Brain_Myeloid-Hippocampus-3m-Myeloid-nan|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CLASP2 NRIP1 CHD9

2.69e-0619373b39d7feaac4ff8f7409cd3d15e8f3c6391367275
ToppCellfrontal_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Crhr2_Efemp1|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype

NRIP1 PCDH18

1.89e-0413672e3a2425ba5ef538dbacab1479e682837ae42a888
ToppCellPBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_B|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k)

CLASP2 CHD9

2.71e-04163726bed27d2f67a430a847da5eb47878d14b4949c45
ToppCellprimary_visual_cortex-Neuronal-GABAergic_neuron-Vip-Vip_Crispld2_Htr2c|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype

CITED2 PCDH18

2.77e-0416572c6b23013d77fa9aa967b76e451c8e42b0a657c30
ToppCellfrontal_cortex-Neuronal-GABAergic_neuron-Vip|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype

CITED2 PCDH18

2.98e-04171725efd15300f865ebf651e0888265cbd717bc3b9d3
ToppCellfacs|World / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CLASP2 CHD9

3.01e-0417272a2d0a64ebf09d219a07d6bbad1056bad6d46b9be
ToppCellPBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_B-B_cell|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k)

CLASP2 CHD9

3.05e-0417372d56e337eae727a29cd53cfd628e1b3c0a98e1f51
ToppCelldroplet-Heart-nan-3m|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CHD9 PCDH18

3.15e-0417672749b47eac5436fa34e0d243ffbc6f1897f4e431e
ToppCellHippocampus-Neuronal-Inhibitory|Hippocampus / BrainAtlas - Mouse McCarroll V32

CITED2 UBR5

3.37e-0418272b54ae650c04dfd0759c5f5e752b9bf684dd36516
ToppCell5'-Airway_Nasal-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell-Mast_cells-|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

CLASP2 NRIP1

3.37e-04182724cd5eb13f78f4f377932c50ac2acb4ac0cd14c12
ToppCell3'_v3-lymph-node_spleen-Lymphocytic_Invariant-Inducer-like|lymph-node_spleen / Manually curated celltypes from each tissue

CITED2 NRIP1

3.45e-0418472d97471a4fe17cba6880ccf1a04cc00c741558124
ToppCellprimary_visual_cortex-Neuronal-GABAergic_neuron|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype

CITED2 PCDH18

3.48e-0418572739260f8abebaf10a5cc49d91726278579e26170
ToppCellCOVID-19_Convalescent-PLT_4|World / Disease Group and Platelet Clusters

CITED2 CHD9

3.52e-04186725954a1e3ffafb33f2a9bc87af3343f304fda4c92
ToppCell3'-Adult-LargeIntestine-Mesenchymal-fibroblastic-Stromal_2_(NPY+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

CITED2 PCDH18

3.52e-0418672d3509a579871ba6a8c4edd6137b28f271c9dbe70
ToppCellfacs-Brain_Myeloid-Striatum-3m-Myeloid-nan|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CLASP2 NRIP1

3.64e-04189726dd4ec5ce4beb856f0d2d1654e3c4676d1d63736
ToppCellfacs-Brain_Myeloid-Striatum-3m-Myeloid-microglial_cell|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CLASP2 NRIP1

3.64e-0418972875df61ee48baa5142ba4d2427bdec1c53e5a828
ToppCellfacs-Brain_Myeloid-Striatum-3m-Myeloid|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CLASP2 NRIP1

3.64e-04189723ae479ec7e00c57127cbe51a398329b10ca9848c
ToppCellfacs-Brain_Myeloid-Striatum-3m|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CLASP2 NRIP1

3.64e-041897297ef5215d841ff366a3e3682cd9bd04100cbfde0
ToppCellPCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung

CITED2 PCDH18

3.67e-04190727986586b7c82e91c71102cc8c4d7a689ae63ab4d
ToppCelldroplet-Large_Intestine-COLON_PROXIMAL-30m-Epithelial|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

NRIP1 CHD9

3.71e-041917209db184cb90fe282a14474d7217068c58092c6f8
ToppCell10x3'2.3-week_17-19-Lymphocytic_B-B_lineage-pro_B_progenitor|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

NRIP1 CHD9

3.71e-041917240813c397f533c2f4a6359a77757f736b6d9e07d
ToppCelldroplet-Large_Intestine-COLON_PROXIMAL|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

NRIP1 CHD9

3.71e-041917260c986d2dcbc19d9338c03da6cb5e1d92fd48f8e
ToppCelldroplet-Large_Intestine-COLON_PROXIMAL-30m|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

NRIP1 CHD9

3.71e-0419172973117730d6ba5f127e7a0bfabfd0ff2ca7ac131
ToppCellCOVID-19_Convalescent-PLT_4|COVID-19_Convalescent / Disease Group and Platelet Clusters

CITED2 CHD9

3.83e-0419472ce1fad4e76a87f0c35e430ed1f2262395df882fd
ToppCell3'-Adult-LargeIntestine-Mesenchymal-fibroblastic-Stromal_3_(C7+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

CITED2 PCDH18

3.83e-0419472e2db75f4de114631b8bda4e188f84446545538b7
ToppCell343B-Myeloid-Macrophage-FABP4+_Macrophage_2|Macrophage / Donor, Lineage, Cell class and subclass (all cells)

NRIP1 CHD9

3.83e-04194726cf9d59aec8dd18fa2fc1652ddd0f5ef1f24bcb6
ToppCellControl-MAIT|Control / Disease condition and Cell class

NRIP1 CHD9

3.83e-0419472ed99f8bff6766795fc396990604366f49ff58181
ToppCell10x3'2.3-week_14-16-Lymphocytic_B-B_lineage-pro_B_progenitor|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

NRIP1 CHD9

3.83e-0419472f64da5f62e29253d60b9546edf734ba5c17daae1
ToppCellfacs-Brain_Myeloid-Hippocampus|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

NRIP1 CHD9

3.87e-0419572a1478021a3ed0e779716393124ca2a7770c433b7
ToppCellLPS_IL1RA_TNF|World / Treatment groups by lineage, cell group, cell type

CITED2 CHD9

3.95e-04197720a6550dce156fc81f15b1e7830d331ca50d87d06
ToppCell10x3'2.3-week_14-16-Lymphocytic_B-B_lineage-pre_pro_B_progenitor|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

NRIP1 CHD9

3.99e-04198728aa4149d2c1cec73cfd654db093252ec8ec5ef68
ToppCellILEUM-inflamed-(6)_ILC-(6)_ILC3|(6)_ILC / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)

CITED2 NRIP1

4.03e-041997202879df850b0c72b57d7b22cfc43f3407e182dcb
ToppCellTracheal-NucSeq|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations

CLASP2 UBR5

4.03e-041997294b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell5'-GW_trimst-1-SmallIntestine-Mesenchymal-immature_mesenchymal_cell|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

CHD9 PCDH18

4.07e-04200724234bdc70a9941d4bf77148d75bd271e0c114b88
Drugirinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A

CLASP2 UBR5 NRIP1 CHD9

1.13e-07174747530_DN
Drugirinotecan HCl; Down 200; 100uM; PC3; HT_HG-U133A

UBR5 NRIP1 CHD9

1.43e-05171737535_DN
Drugirinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A

UBR5 NRIP1 CHD9

1.75e-05183737498_DN
Drugtestosterone-3-carboxymethyloxime-bovine serum albumin conjugate

CITED2 NRIP1 NCOA6

1.80e-0518573ctd:C045037
DrugN6-methyladenosine [1867-73-8]; Down 200; 14.2uM; HL60; HT_HG-U133A

CITED2 CLASP2 UBR5

2.02e-05192731271_DN
DrugGliclazide [21187-98-4]; Down 200; 12.4uM; HL60; HG-U133A

CLASP2 UBR5 CHD9

2.28e-05200731720_DN
DrugAldosterone

NRIP1 NCOA6

2.47e-047972ctd:D000450
DrugParthenolide [20554-84-1]; Down 200; 16.2uM; MCF7; HT_HG-U133A

CITED2 NRIP1

1.04e-03163722885_DN
DrugRetinoic acid [302-79-4]; Up 200; 13.4uM; HL60; HG-U133A

NRIP1 CHD9

1.04e-03163721548_UP
DrugClorgyline

NRIP1 CHD9

1.11e-0316872ctd:D003010
Drugciprofibrate

CHD9 NCOA6

1.14e-0317072CID000002763
DrugTrichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA

NRIP1 NCOA6

1.14e-03170721050_DN
DrugTrichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A_EA

NRIP1 NCOA6

1.16e-03172721072_DN
DrugTrichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A

NRIP1 NCOA6

1.19e-03174721659_DN
DrugTrichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A_EA

NRIP1 NCOA6

1.20e-03175721014_DN
DrugSAHA; Down 200; 10uM; MCF7; HT_HG-U133A_EA

NRIP1 NCOA6

1.20e-03175721058_DN
DrugTrichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

NRIP1 NCOA6

1.22e-03176726932_DN
DrugSAHA; Down 200; 10uM; MCF7; HT_HG-U133A

NRIP1 NCOA6

1.23e-03177721645_DN
DrugTrichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

NRIP1 NCOA6

1.23e-03177726972_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

NRIP1 NCOA6

1.24e-03178727245_DN
DrugTrichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA

NRIP1 NCOA6

1.24e-03178721112_DN
Drugfisetin; Down 200; 50uM; PC3; HG-U133A

NRIP1 NCOA6

1.24e-0317872579_DN
DrugMG-132; Down 200; 21uM; MCF7; HT_HG-U133A_EA

CITED2 CHD9

1.26e-03179721140_DN
DrugCamptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A

NRIP1 CHD9

1.27e-03180724541_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HG-U133A

NRIP1 NCOA6

1.30e-03182721891_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HG-U133A

NRIP1 NCOA6

1.30e-03182721951_DN
DrugCamptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A

NRIP1 CHD9

1.30e-03182723887_DN
DrugICI 182,780; Down 200; 1uM; MCF7; HT_HG-U133A

NRIP1 CHD9

1.31e-03183726925_DN
DrugParthenolide [20554-84-1]; Down 200; 16.2uM; MCF7; HT_HG-U133A

CITED2 NRIP1

1.31e-03183725530_DN
Drug0175029-0000 [211245-78-2]; Down 200; 10uM; MCF7; HT_HG-U133A

CITED2 CHD9

1.33e-03184724713_DN
DrugCamptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A

NRIP1 CHD9

1.33e-03184722321_DN
DrugDoxorubicin hydrochloride [25316-40-9]; Down 200; 6.8uM; PC3; HT_HG-U133A

NRIP1 CHD9

1.33e-03184724610_DN
DrugDoxorubicin hydrochloride [25316-40-9]; Down 200; 6.8uM; MCF7; HT_HG-U133A

CITED2 NRIP1

1.33e-03184725671_DN
Drug17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A_EA

CITED2 NRIP1

1.33e-03184721064_DN
DrugAmoxicillin [26787-78-0]; Down 200; 11uM; MCF7; HT_HG-U133A

CITED2 NRIP1

1.34e-03185722620_DN
Drugtyrphostin AG-825; Down 200; 25.2uM; MCF7; HT_HG-U133A_EA

NRIP1 CHD9

1.34e-03185721114_DN
DrugGW8510; Down 200; 10uM; MCF7; HT_HG-U133A

CITED2 NRIP1

1.37e-03187727080_DN
DrugPrimaquine diphosphate [63-45-6]; Down 200; 8.8uM; MCF7; HT_HG-U133A

UBR5 CHD9

1.39e-03188724845_DN
DrugLY 294002; Down 200; 10uM; MCF7; HT_HG-U133A_EA

CLASP2 UBR5

1.40e-03189721065_DN
Drug15d-PGJ2; Down 200; 10uM; HL60; HT_HG-U133A

CITED2 NRIP1

1.42e-03190721172_DN
DrugDaunorubicin hydrochloride [23541-50-6]; Down 200; 7uM; MCF7; HT_HG-U133A

CITED2 NRIP1

1.42e-03190724983_DN
Drugradicicol; Up 200; 0.1uM; MCF7; HG-U133A

CITED2 CLASP2

1.43e-0319172489_UP
Drugtrichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A

NRIP1 NCOA6

1.43e-03191727503_DN
Drugscriptaid; Down 200; 10uM; PC3; HT_HG-U133A

UBR5 NRIP1

1.44e-03192726919_DN
Drugcarmustine; Up 200; 100uM; MCF7; HT_HG-U133A

CITED2 UBR5

1.44e-03192726914_UP
DrugHexamethonium dibromide dihydrate [55-97-0]; Down 200; 10uM; HL60; HG-U133A

CLASP2 NRIP1

1.46e-03193721982_DN
Drug0316684-0000 [391209-55-5]; Up 200; 10uM; PC3; HT_HG-U133A

CITED2 NRIP1

1.46e-03193727098_UP
DrugThioguanosine [85-31-4]; Down 200; 12.6uM; HL60; HT_HG-U133A

CITED2 CLASP2

1.47e-03194721264_DN
DrugAmprolium hydrochloride [137-88-2]; Down 200; 12.6uM; HL60; HG-U133A

CITED2 UBR5

1.49e-03195721979_DN
Drugtroglitazone; Up 200; 10uM; PC3; HG-U133A

CITED2 UBR5

1.49e-0319572431_UP
Drugphentolamine; Down 200; 11.5uM; MCF7; HT_HG-U133A_EA

NRIP1 CHD9

1.49e-03195721138_DN
DrugVerapamyl hydrochloride [152-11-4]; Up 200; 8.2uM; PC3; HG-U133A

CITED2 CHD9

1.49e-03195721927_UP
DrugSC-560; Up 200; 10uM; MCF7; HT_HG-U133A

CITED2 UBR5

1.49e-03195726913_UP
DrugAdiphenine hydrochloride [50-42-0]; Up 200; 11.4uM; PC3; HT_HG-U133A

CITED2 CHD9

1.49e-03195721831_UP
DrugDacarbazine [4342-03-4]; Down 200; 22uM; HL60; HG-U133A

CITED2 NRIP1

1.49e-03195721762_DN
DrugMetronidazole [443-48-1]; Down 200; 23.4uM; PC3; HG-U133A

UBR5 NRIP1

1.50e-03196721921_DN
Drugcobalt(II) chloride hexahydrate; Up 200; 100uM; MCF7; HG-U133A

UBR5 NRIP1

1.50e-0319672379_UP
DrugSC-58125; Down 200; 10uM; SKMEL5; HG-U133A

CLASP2 CHD9

1.50e-0319672507_DN
DrugHesperetin [520-33-2]; Down 200; 13.2uM; HL60; HG-U133A

CLASP2 NRIP1

1.50e-03196722031_DN
DrugSulfameter [651-06-9]; Down 200; 14.2uM; MCF7; HT_HG-U133A

CITED2 CLASP2

1.50e-03196723453_DN
DrugChrysene-1,4-quinone [100900-16-1]; Down 200; 15.4uM; PC3; HT_HG-U133A

CLASP2 UBR5

1.50e-03196727139_DN
DrugLY294002; Up 200; 0.1uM; MCF7; HG-U133A

CLASP2 CHD9

1.50e-0319672424_UP
DrugIsoxicam [34552-84-6]; Up 200; 12uM; PC3; HT_HG-U133A

CITED2 CLASP2

1.50e-03196721820_UP
DrugEnoxacin [74011-58-8]; Up 200; 12.4uM; HL60; HG-U133A

CITED2 UBR5

1.52e-03197721597_UP
DrugRitodrine hydrochloride [23239-51-2]; Down 200; 12.4uM; MCF7; HT_HG-U133A

CITED2 CLASP2

1.52e-03197722635_DN
DrugBuspirone hydrochloride [33386-08-2]; Down 200; 9.4uM; MCF7; HT_HG-U133A

CLASP2 UBR5

1.52e-03197725343_DN
DrugOxethazaine [126-27-2]; Down 200; 8.6uM; PC3; HG-U133A

UBR5 NRIP1

1.52e-03197721903_DN
DrugEtofylline [519-37-9]; Down 200; 17.8uM; PC3; HT_HG-U133A

CITED2 CLASP2

1.52e-03197722093_DN
DrugLobelanidine hydrochloride [6112-86-3]; Down 200; 10.6uM; HL60; HG-U133A

UBR5 CHD9

1.52e-03197721747_DN
Drugestradiol, USP; Down 200; 0.1uM; HL60; HT_HG-U133A

CITED2 CLASP2

1.52e-03197721149_DN
DrugFlumequine [42835-25-6]; Down 200; 15.4uM; HL60; HG-U133A

NRIP1 CHD9

1.52e-03197721429_DN
DrugNicergoline; Down 200; 8.2uM; HL60; HG-U133A

CLASP2 NRIP1

1.52e-03197721374_DN
DrugNifedipine [21829-25-4]; Down 200; 11.6uM; PC3; HT_HG-U133A

CITED2 CLASP2

1.54e-03198727303_DN
DrugBupropion hydrochloride [31677-93-7]; Down 200; 14.4uM; HL60; HG-U133A

NRIP1 CHD9

1.54e-03198721564_DN
DrugSB 203580; Up 200; 1uM; MCF7; HT_HG-U133A

CITED2 UBR5

1.54e-03198726915_UP
DrugSyrosingopine [84-36-6]; Down 200; 6uM; HL60; HG-U133A

CITED2 NRIP1

1.54e-03198721761_DN
DrugZidovudine, AZT [30516-87-1]; Down 200; 15uM; HL60; HG-U133A

CLASP2 NRIP1

1.54e-03198721595_DN
DrugTrimethobenzamide hydrochloride [554-92-7]; Up 200; 9.4uM; HL60; HG-U133A

UBR5 NRIP1

1.54e-03198722002_UP
DrugZaprinast [37762-06-4]; Up 200; 14.8uM; HL60; HG-U133A

NRIP1 CHD9

1.54e-03198721611_UP
DrugNaproxen [22204-53-1]; Down 200; 17.4uM; HL60; HT_HG-U133A

CITED2 UBR5

1.54e-03198721869_DN
DrugAconitine [302-27-2]; Down 200; 6.2uM; HL60; HG-U133A

UBR5 CHD9

1.54e-03198721784_DN
DrugMetanephrine hydrochloride DL [881-95-8]; Down 200; 17.2uM; MCF7; HT_HG-U133A

CITED2 CHD9

1.54e-03198725334_DN
Diseasebreast cancer (is_implicated_in)

UBR5 NCOA6

5.30e-0415072DOID:1612 (is_implicated_in)
DiseaseAlzheimer disease, gastroesophageal reflux disease

UBR5 NRIP1

1.22e-0322872EFO_0003948, MONDO_0004975
DiseaseAgents acting on the renin-angiotensin system use measurement

NRIP1 PCDH18

2.60e-0333572EFO_0009931
Diseasemonocyte percentage of leukocytes

NRIP1 CHD9

1.18e-0273172EFO_0007989

Protein segments in the cluster

PeptideGeneStartEntry
ERGQMGSRQSHNSHQ

PCDH18

786

Q9HCL0
NSHMGNNASRPHSAN

NRIP1

1126

P48552
HMAQQHGDPATTANN

NCOA6

796

Q14686
PHVQAMQGNSASGNH

NCOA6

831

Q14686
QNGSPFHQQGHSHSM

CHD9

136

Q3L8U1
AAGHQMNGTNQHFRD

CITED2

141

Q99967
HNHLRNTGNGTQSSM

CLASP2

876

O75122
SSHANGAAQAPRSMQ

UBR5

1701

O95071